Patents Examined by Michelle S Horning
-
Patent number: 11939598Abstract: The present invention concerns a production bacterial cell for producing phage particles or phage-derived delivery vehicles, said production bacterial cell stably comprising at least one phage structural gene(s) and at least one phage DNA packaging gene(s), said phage structural gene(s) and phage DNA packaging gene(s) being derived from a first type of bacteriophage, wherein the expression of at least one of said phage structural gene(s) and/or at least one of said phage DNA packaging gene(s) in said production bacterial cell is controlled by at least one induction mechanism, and wherein said production bacterial cell is from a bacterial species or strain different from the bacterial species or strain from which said first type of bacteriophage comes and/or that said first type of bacteriophage targets.Type: GrantFiled: May 18, 2023Date of Patent: March 26, 2024Assignee: Eligo BioscienceInventors: Jesus Fernandez Rodriguez, Antoine Decrulle, Aymeric Leveau, Ines Canadas Blasco, Aurélie Mathieu, Thibault Carlier
-
Patent number: 11938180Abstract: The invention provides poliovirus like particles, which comprise stabilised empty poliovirus capsids that retain their native antigenic properties. The invention also provides methods of identifying mutations useful in the production of such poliovirus like particles, methods of producing such poliovirus like particles and the use of such poliovirus like particles in methods of vaccinating against poliovirus.Type: GrantFiled: January 17, 2018Date of Patent: March 26, 2024Assignee: SECRETARY OF STATE FOR HEALTH AND SOCIAL CARE, MINISTERIAL CORRESPONDENCE AND PUBLIC ENQUIRIES, DEPARTMENT OF HEALTH AND SOCIAL CAREInventor: Andrew Macadam
-
Patent number: 11932857Abstract: Compositions and methods for stimulating toll-like receptor 9 (TLR9) are provided. More particularly, immunostimulatory oligonucleotides, methods of enhancing immunostimulatory properties of oligonucleotides, and methods of eliciting immune responses are disclosed herein.Type: GrantFiled: December 7, 2018Date of Patent: March 19, 2024Assignee: Elanco Animal Health GmbHInventor: Thomas Ilg
-
Patent number: 11920185Abstract: The present invention provides inactivated microbes, methods of preparing and using the same, as well as compositions and kits containing the same. The inactivated microbes are useful in the formulation of internal control reagents for use in recombinant nucleic acid techniques, especially nucleic acid amplification, e.g., by the polymerase chain reaction (PCR).Type: GrantFiled: April 19, 2021Date of Patent: March 5, 2024Assignee: Roche Molecular Systems, Inc.Inventor: Ellen Fiss
-
Patent number: 11919924Abstract: The present invention relates to a method for purifying adalimumab or a biosimilar thereof from a sample comprising adalimumab or a biosimilar thereof and impurities, through the use of hydroxyapatite resin in a Bind/Elute (B/E) mode under conditions such that the adalimumab or a biosimilar thereof binds to the resin and at least a portion of the impurities remain unbound. The invention is also concerned with a pharmaceutical compositions=of the purified adalimumab or a biosimilar thereof, and adalimumab or a biosimilar thereof obtainable by the process of the invention.Type: GrantFiled: December 20, 2018Date of Patent: March 5, 2024Assignee: FRESENIUS KABI DEUTSCHLAND GMBHInventors: Harry-James Sutter, Matteo Costioli, Hervé Broly
-
Patent number: 11905516Abstract: The present invention relates to a vector, preferably included in a delivery vehicle, comprising no more than (100), preferably no more than (10), restriction sites recognized by the restriction enzymes encoded by each bacterium of a group of bacteria of interest. The invention also relates to the use of said vector, preferably included in a delivery vehicle, as a drug, especially in the treatment of a disease in a patient in need thereof.Type: GrantFiled: February 2, 2018Date of Patent: February 20, 2024Assignees: ELIGO BIOSCIENCE, INSTITUT PASTEURInventors: Antoine Decrulle, Jesus Fernandez Rodriguez, Xavier Duportet, David Bikard
-
Patent number: 11873524Abstract: Disclosed herein are methods and systems for rapid detection of microorganisms in a sample. A genetically modified bacteriophage is also disclosed which comprises an indicator gene in the late gene region. The specificity of the bacteriophage, such as Salmonella-specific bacteriophage, allows detection of a specific microorganism, such as Salmonella spp. and an indicator signal may be amplified to optimize assay sensitivity.Type: GrantFiled: January 14, 2019Date of Patent: January 16, 2024Assignee: Laboratory Corporation of America HoldingsInventors: Stephen Erickson, Jose S. Gil, Minh Mindy Bao Nguyen, Dwight Lyman Anderson, Jessica Stach
-
Patent number: 11845996Abstract: A method for testing for target Mycobacteria in a reaction mixture comprising the steps of: providing a reaction mixture; admixing a bacteriophage with the reaction mixture under conditions suitable to allow the bacteriophage to infect any target Mycobacteria present in the reaction mixture; allowing time for the bacteriophage to lyse infected live target Mycobacteria; and analysing in said reaction mixture DNA from the lysed Mycobacteria to identify a signature DNA sequence that occurs in the target Mycobacteriumspedes.Type: GrantFiled: July 8, 2019Date of Patent: December 19, 2023Assignee: PBD BIOTECH LIMITEDInventors: Catherine Rees, Benjamin Swift
-
Patent number: 11839652Abstract: This application relates to compositions comprising one or more CpG oligodeoxynucleotides complexed to nanoparticles comprising a gemini surfactant and optionally a muco-adhesive polymer, which can be used for intrapulmonary delivery to induce immunity in feed animals, and the methods of making and uses thereof.Type: GrantFiled: July 17, 2018Date of Patent: December 12, 2023Assignee: University of SaskatchewanInventors: Susantha Gomis, Shelly Popowich, Kalhari Venukala Bandara Goonewardene, Suresh Tikoo, Marianna Foldvari
-
Patent number: 11828758Abstract: A recombinant polypeptide can be used in the diagnosis of the presence of a Zika virus in a patient. The recombinant polypeptide includes SEQ ID NO: 1 or a variant thereof. The recombinant peptide may be a monomer, a dimer, or a hexamer.Type: GrantFiled: October 1, 2020Date of Patent: November 28, 2023Assignee: EUROIMMUN Medizinische Labordiagnostika AGInventors: Katja Steinhagen, Andrea Deerberg, Erik Lattwein, Christiane Radzimski, Jana Böthfür
-
Patent number: 11827693Abstract: The present invention provides methods for treatment or prophylaxis of viruses, particularly influenza virus, by administration of agents, particularly neutralizing antibodies or active fragments thereof, directly to the respiratory tract, including by intranasal or inhalation administration. The invention provides compositions suitable for intranasal or inhalation treatment and administration. The invention includes methods for treatment or prophylaxis combining intranasal or inhalation administration with intraperitoneal or intravenous administration of antibodies.Type: GrantFiled: March 14, 2014Date of Patent: November 28, 2023Assignee: CONTRAFECT CORPORATIONInventors: Michael Wittekind, Adam Vigil
-
Patent number: 11821017Abstract: An enzymatic method is provided for restructuring an affinity ligand bound heterogenous glycoform antibody sample to a substantially homogenous single desired glycoform antibody sample for therapeutic uses and kits for performing the methods. A method for enzymatically altering the Fc region of an affinity ligand bound antibody from a heterogenous glycoform to a substantially homogenous single glycoform comprises: contacting the affinity ligand bound heterogeneous glycoform antibody with a reaction buffer designed for a particular glycoform modification for a time sufficient and under conditions to modify the glycoform of the Fc region to a substantially homogeneous single form; optionally adding one or more nucleotide sugars and/or cofactors; and releasing the substantially homogeneous single glycoform antibody sample from said affinity ligand.Type: GrantFiled: January 7, 2020Date of Patent: November 21, 2023Assignee: University of ManitobaInventors: Venkata Tayi, Michael Butler
-
Patent number: 11780885Abstract: Compounds useful as components of immunogenic compositions for the induction of an immunogenic response in a subject against viral infection, methods for their use in treatment, and processes for their manufacture are provided herein. The compounds comprise a nucleic acid construct comprising a sequence which encodes a Zika virus antigen.Type: GrantFiled: November 15, 2017Date of Patent: October 10, 2023Assignees: GLAXOSMITHKLINE BIOLOGICALS SA, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Kimberly Dowd, Barney S. Graham, Sung-Youl Ko, Wing-Pui Kong, John Mascola, Theodore Pierson, Mayuri Sharma, Dong Yu
-
Patent number: 11779617Abstract: The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Pseudomonas aeruginosa strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.Type: GrantFiled: January 21, 2021Date of Patent: October 10, 2023Assignee: PHERECYDES PHARMAInventors: Flavie Pouillot, Helene Blois
-
Patent number: 11773143Abstract: X-ray crystallography has defined conformational properties of a key functional region of the G protein of respiratory syncytial virus (RSV). Mimics of these epitopes have utility as immunogens, as tools for discovery of antibodies and other monoclonal binding agents, and as pharmacological agents to modulate activity of the host receptors for this viral protein.Type: GrantFiled: October 12, 2018Date of Patent: October 3, 2023Assignees: Trellis Bioscience, LLC, The Regents of the University of CaliforniaInventors: Rebecca Dubois, Stas Fedechkin, Lawrence M. Kauvar
-
Patent number: 11752209Abstract: The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an histidine buffering agent such as histidine (or histidine buffer system such as histidine/imidazolium-histidine), and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.Type: GrantFiled: November 2, 2022Date of Patent: September 12, 2023Assignee: Fresenius Kabi Deutschland GmbHInventors: Gianluca Rinaldi, Silvia Fratarcangeli, Alessandra Del Rio
-
Patent number: 11752208Abstract: The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an histidine buffering agent such as histidine (or histidine buffer system such as histidine/imidiazolium-histidine), and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.Type: GrantFiled: August 11, 2020Date of Patent: September 12, 2023Assignee: Fresenius Kabi Deutschland GmbHInventors: Gianluca Rinaldi, Silvia Fratarcangeli, Alessandra Del Rio
-
Patent number: 11739304Abstract: The present invention concerns a production bacterial cell for producing lytic phage particles or lytic phage-derived delivery vehicles, said production bacterial cell stably comprising at least one phage structural genes and at least one phage DNA packaging genes, said phage structural gene(s) and phage DNA packaging gene(s) being derived from a lytic bacteriophage, wherein the expression of at least one of said phage structural genes and/or at least one of said phage DNA packaging gene(s) in said production bacterial cell is controlled by an induction mechanism.Type: GrantFiled: May 12, 2022Date of Patent: August 29, 2023Assignee: Eligo BioscienceInventors: Jesus Fernandez Rodriguez, Antoine Decrulle, Aymeric Leveau, Ines Canadas Blasco, Aurélie Mathieu, Thibault Carlier
-
Patent number: 11712471Abstract: The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an acetate buffering agent/system such as sodium acetate/acetic acid, and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.Type: GrantFiled: October 13, 2020Date of Patent: August 1, 2023Assignee: Fresenius Kabi Deustschland GmbHInventors: Gianluca Rinaldi, Silvia Fratarcangeli, Alessandra Del Rio
-
Patent number: 11707524Abstract: The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an acetate buffering agent/system such as sodium acetate/acetic acid, and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.Type: GrantFiled: March 11, 2021Date of Patent: July 25, 2023Assignee: Fresenius Kabi Deutschland GmbHInventors: Gianluca Rinaldi, Silvia Fratarcangeli, Alessandra Del Rio